• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    48.77 +0.59 (+1.22%)
    Official Closing Price Updated: 7:00 PM EDT, Jul 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,799,112
    Open 48.83
    Bid (Size) 48.65 (200)
    Ask (Size) 49.26 (400)
    Prev. Close 48.18
    Today's Range 48.70 - 49.52
    52wk Range 35.12 - 71.80
    Shares Outstanding N/A
    Dividend Yield 5.23%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗
    Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs. 
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
    There are plenty of reasons to love these companies. 
    Via The Motley Fool

    Performance

    YTD
    -6.9%
    -6.9%
    1 Month
    +2.9%
    +2.9%
    3 Month
    +18.5%
    +18.5%
    6 Month
    -21.7%
    -21.7%
    1 Year
    -31.0%
    -31.0%

    More News

    Read More
    News headline image
    3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    "Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗
    Via The Motley Fool
    News headline image
    Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
    Via FinancialNewsMedia
    News headline image
    Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
    Via The Motley Fool
    News headline image
    The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗
    Via The Motley Fool
    News headline image
    3 High-Yield Dividend Stocks to Buy and Hold ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    This GLP-1 Stock Could Double by 2030. Here's Why ↗
    Via The Motley Fool
    News headline image
    2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗
    Via The Motley Fool
    News headline image
    Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗
    Via The Motley Fool
    News headline image
    3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗
    Via The Motley Fool
    News headline image
    Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
    Via The Motley Fool
    News headline image
    Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗
    Via The Motley Fool
    News headline image
    Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week ↗
    Via The Motley Fool
    News headline image
    Is It Too Late to Buy Eli Lilly? ↗
    Via The Motley Fool
    News headline image
    Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗
    Via The Motley Fool
    News headline image
    Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗
    Via The Motley Fool
    Topics Supply Chain
    News headline image
    3 Reasons to Buy Novo Nordisk Stock ↗
    Via The Motley Fool
    News headline image
    U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗
    Via The Motley Fool
    News headline image
    As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗
    Via MarketBeat
    News headline image
    Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 48.77
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 07/24/26 07:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.